Skip to main content
Clinical Trials/IRCT2015080223470N1
IRCT2015080223470N1
Completed
Phase 2

Comparison of Haloperidol and Opium Tincture in the control of clinical signs associated with methamphetamine

Vice Chancellor for Research, University of Medical Sciences0 sites70 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
Vice Chancellor for Research, University of Medical Sciences
Enrollment
70

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 65 years (—)
Sex
All

Inclusion Criteria

  • Dependence on methamphetamine (more than 10 times the regular use of methamphetamine or 10 days); Urine tests positive for methamphetamine; Age 18\-65 years; Independence and no use of drugs or other addictive drugs at the time of presentation; Complete the consent form; To track patient;
  • Exclusion criteria: Unwillingness person to continue treatment; Patient self\-medication or participate in another study; Other addictive drugs or alcohol or drug use during the study period; Non\-compliance with medication orders during the study; Coming out of treatment (imprisonment, death, ...); Any behavior that resulted in dismissal laws rehab clinic patient; There are other mental disorders that require treatment or the risk of suicide; Significant diseases of the Thyroid, Kidney, Liver, Gastrointestinal or Cardiovascular; History of diabetes or Heart attack, Seizures, Glaucoma, Tick, Tardive dyskinesia; Female without adequate contraception pregnancy or lactation; Tincture of opium abusers; A history of allergy to Haloperidol; Simultaneous treatment with antipsychotics or mood stabilizers or CYP 2D6 inhibitors Contains: Amiodarone, Bupropion, Celecoxib, Cimetidine, Chlorpromazine, Clomipramine, Fluoxetine, Haloperidol, Methadone, Moclobemide, Paroxetine, Quinidine, Ritonavir, Sertraline, Terbinafine and Thioridazine; So dangerous side effects of medications or the patient is intolerable.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Vice Chancellor for Research, University of Medical Sciences

Similar Trials